No Data
No Data
Indaptus Therapeutics Shares Are Trading Higher. HC Wainwright & Co. Reiterated a Buy Rating on the Stock.
Express News | HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Indaptus Therapeutics Shares Are Trading Higher After the Company Announced It Began Initiating the Unrestricted Enrollment of Patients for Its Decoy20 Phase 1 Weekly Dosing Trial.
Indaptus Therapeutics CSO to Speak on Webinar About Cancer Immunotherapy
12 Health Care Stocks Moving In Friday's Intraday Session
Indaptus Therapeutics Files to Sell 1.64M Shares of Common Stock for Holders
No Data
No Data